Pharmaceutical Investing News

Pharmaceutical Investing

MediciNova Announces Collaboration with the University of Sydney Concord Cancer Centre

Pharmaceutical Investing

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a pilot study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy. As quoted in the press release: The clinical trial is a collaborative effort between MediciNova, …

MediciNova a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it plans to initiate a pilot study to evaluate MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy.

As quoted in the press release:

The clinical trial is a collaborative effort between MediciNova, Inc. and Dr. Janette Vardy, Professor of Cancer Medicine, University of Sydney Concord Cancer Centre in Australia. The proposed clinical trial will evaluate MN-166 (ibudilast) as a potential treatment for individuals with chemotherapy-induced peripheral neuropathy.  A Concord Cancer Centre Research grant will provide funding for this study and MediciNova will provide study drug.

Click here to read the full press release.

australiacancerchemotherapymedicinovamn-166nasdaq global marketPharmaceutical Investing

MARKETS

Markets
TSX19062.91+345.79
TSXV647.33+15.54
DOW31500.68+823.32
S&P 5003911.74+116.01
NASD11607.62+375.43
ASX6528.40+19.90

COMMODITIES

Commodities
Gold1836.17+5.17
Silver21.41+0.27
Copper3.78+0.04
Palladium1956.43+79.44
Platinum919.00+8.01
Oil107.61-0.01
Heating Oil4.240.00
Natural Gas6.14-0.08

DOWNLOAD FREE REPORTS

Browse more resource reports ≫
Browse more technology reports ≫
Browse more life science reports ≫

BROWSE COMPANIES BY SECTOR

×